|
Abetalipoproteinemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results illustrate selectivity in the effects of PTPs in a cellular context and suggest that PTP1B may function as a specific, negative regulator of p210 bcr-abl signalling in vivo.
|
9566916 |
1998 |
|
Acute leukemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Deficiency in Protein Tyrosine Phosphatase PTP1B Shortens Lifespan and Leads to Development of Acute Leukemia.
|
29122767 |
2018 |
|
Adult Classical Hodgkin Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively, these data indicate that PTP1BΔ6 is a positive regulator of JAK/STAT signaling in cHL.
|
28082443 |
2017 |
|
Adult Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study PTPIP51 and its interacting partners 14-3-3β, PTP1B, c-Src, Raf-1 as well as EGFR were investigated in human glioblastoma.
|
21972092 |
2011 |
|
Adult Hodgkin Lymphoma
|
0.310 |
Biomarker
|
disease |
CTD_human |
Moreover, silencing of PTPN1 by RNA interference in Hodgkin lymphoma cell line KM-H2 resulted in hyperphosphorylation and overexpression of downstream oncogenic targets.
|
24531327 |
2014 |
|
Adult Hodgkin Lymphoma
|
0.310 |
Biomarker
|
disease |
BEFREE |
Moreover, silencing of PTPN1 by RNA interference in Hodgkin lymphoma cell line KM-H2 resulted in hyperphosphorylation and overexpression of downstream oncogenic targets.
|
24531327 |
2014 |
|
Adult Lymphoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
As inactivation mutations in PTPN1 and PTPN2 are restricted to distinct subsets of leukemia and lymphoma, a future challenge will be to identify in which cellular contexts do they contributing to the initiation or maintenance of leukemogenesis or lymphomagenesis.
|
26817397 |
2016 |
|
Adult Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
We found an increase of genomic complexity with lymphoma progression from small to large cytology, and identified gains of prominent (proto) oncogenes such as REL, BCL11A, ETS1, PTPN1, PTEN and KRAS which were found exclusively in the large cell variants.
|
22890838 |
2013 |
|
Altitude Hypoxia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Genetic variation in PTPN1 contributes to metabolic adaptation to high-altitude hypoxia in Tibetan migratory locusts.
|
30478313 |
2018 |
|
Alzheimer's Disease
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Susceptibility to diet-induced obesity and glucose intolerance in the APP (SWE)/PSEN1 (A246E) mouse model of Alzheimer's disease is associated with increased brain levels of protein tyrosine phosphatase 1B (PTP1B) and retinol-binding protein 4 (RBP4), and basal phosphorylation of S6 ribosomal protein.
|
21538175 |
2011 |
|
Alzheimer's Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
Taken together, these results identified the miR-124/PTPN1 pathway as a critical mediator of synaptic dysfunction and memory loss in AD, and the miR-124/PTPN1 pathway could be considered as a promising novel therapeutic target for AD patients.
|
28965984 |
2018 |
|
Alzheimer's Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
We propose that PTP1B inhibition may represent an attractive and yet unexplored therapeutic approach to correct aberrant signaling pathways linked to AD.
|
28197094 |
2017 |
|
Alzheimer's Disease
|
0.050 |
PosttranslationalModification
|
disease |
BEFREE |
Meanwhile, ferulic acid could markedly ameliorate spatial memory of diabetic rats in Morris water maze (MWM) and decrease AD-like pathologic changes (Aβ deposition and Tau phosphorylation) in the hippocampus, which might be correlated with the inhibition of inflammatory cytokines release and reduction of protein tyrosine phosphatase 1B (PTP1B) expression.
|
28988132 |
2017 |
|
Alzheimer's Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
In summary, this study provides new evidence that aging-related PTP1B increasing, contributing to insulin resistance and the onset of the AD.
|
29421605 |
2018 |
|
Amnesia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, these results identified the miR-124/PTPN1 pathway as a critical mediator of synaptic dysfunction and memory loss in AD, and the miR-124/PTPN1 pathway could be considered as a promising novel therapeutic target for AD patients.
|
28965984 |
2018 |
|
anaphylaxis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Here we show that Sirt1 negatively regulates FcεRI-stimulated mast cell activation and anaphylaxis through two mutually regulated pathways involving AMP-activated protein kinase (AMPK) and protein tyrosine phosphatase 1B (PTP1B).
|
28744004 |
2017 |
|
Androgenetic Alopecia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Both can be ameliorated by dietary phytochemicals, such as specific classes of phenols (isoflavones, phenolic methoxy abietanes, hydroxylated anthraquinones) or polycyclic triterpenes (sterols, lupanes), by dual inhibition of key enzymes in AGA (5α-reductase) and insulin resistance (ie., DPP-4 or PTP1B) or agonism of nuclear receptors (PPARγ).
|
30195058 |
2018 |
|
Anxiety Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
The reduction of PTP1B in the CeA may be a strategy for the treatment of obesity, insulin resistance and anxiety disorders.
|
28403933 |
2017 |
|
Aortic Valve Stenosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Consistently, we found elevated activity of protein tyrosine phosphatase 1B (PTP1B) at 10 and 20 weeks, which may blunt insulin action by dephosphorylating insulin receptor β. PTP1B activity was also significantly increased in left ventricular samples of patients with systolic dysfunction undergoing aortic valve replacement because of aortic stenosis.
|
29929988 |
2018 |
|
Arteriosclerosis
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Here we demonstrate that inhibiting the activity of PTP1B specifically in myeloid lineage cells protects against atherosclerotic plaque formation, under atherogenic conditions, in an ApoE<sup>-/-</sup> mouse model of atherosclerosis.
|
28752048 |
2017 |
|
Arteriosclerosis
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Genetic variation in PTPN1, a diabetes susceptibility gene, was investigated for a role in diabetic atherosclerosis.
|
16505227 |
2006 |
|
Arteriosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our findings are the first to demonstrate that PTP1B inhibitors could be used in prevention and reversal of atherosclerosis development and reduction in CVD risk.
|
28899902 |
2017 |
|
Atherogenic dyslipidaemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
PTP 1B SNPs may interact with environmental factors to induce more severe phenotypes, e.g. atherogenic dyslipidaemia, in morbidly obese subjects.
|
15235769 |
2004 |
|
Atherosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our findings are the first to demonstrate that PTP1B inhibitors could be used in prevention and reversal of atherosclerosis development and reduction in CVD risk.
|
28899902 |
2017 |
|
Atherosclerosis
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Genetic variation in PTPN1, a diabetes susceptibility gene, was investigated for a role in diabetic atherosclerosis.
|
16505227 |
2006 |